Purpose Tumors are thought to differ in their response to cytotoxic agents for a variety of
reasons including cell cycle kinetics, degree of hypoxia, differential repair, and ability to …

In the present study, we report the characterization of the p53 tumor suppressor pathway in
the 60 cell lines of the National Cancer Institute (NCI) anticancer drug screen, as well as …

Abstract Paclitaxel (PTX), a microtubule-active agent, blocks cell proliferation by inhibiting
mitotic progression leading to mitotic and postmitotic arrest and cell death. Here we …

Paclitaxel-induced cytotoxicity, cell cycle perturbation, and apoptosis were determined in a
human ovarian cancer cell line expressing wt p53 (A2780) and in a subclone (A2780/E6) …

Human lymphoblastoid cells were transfected with expression vectors containing p53 cDNA
mutated at either codon 135 or 246. The cells were subjected to cisplatin treatment or γ …

Paclitaxel exerts its cytotoxic effect by kinetic suppression of microtubules that block cells in
the G2/M phase of the cell cycle and trigger apoptosis. To investigate apoptosis induced by …

Many tumor types have p53 and/or RB mutations, and it is unclear what role the mutations of
these tumor suppressor genes have on the efficacy of chemotherapeutic agents. The effect …

Purpose: The antitumor agent paclitaxel (Taxol®) has been shown to arrest cells in mitosis
through microtubule stabilization and to induce apoptosis. The tumor suppressor gene p53 …

Nine human ovarian cancer cell lines that express wild-type (wt) or mutated p53 were used
to evaluate the cytotoxicity induced by paclitaxel. The IC50 calculated in the five mutated …

A widely held tenet of present day oncology is that tumor cells treated with anticancer agents
die from apoptosis, and that cells resistant to apoptosis are resistant to cancer treatment. We …